Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TRISHA WISE-DRAPER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1306162367
CMS profile
1348174
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$14,141.99

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $8,235.00 2
Genmab U.S., Inc. $5,764.51 10
EMD Serono, Inc. $142.48 3

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TRISHA WISE-DRAPER

NPI 1306162367 · CMS profile ID 1348174

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306162367?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306162367?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306162367?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1306162367?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $14,141.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $6,100.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141633371 CMS
Genmab U.S., Inc. $4,585.0008/30/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833123 CMS
Genmab U.S., Inc. $44.0008/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833109 CMS
Genmab U.S., Inc. $65.0708/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833111 CMS
Genmab U.S., Inc. $50.7908/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833117 CMS
Genmab U.S., Inc. $26.7708/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833119 CMS
Genmab U.S., Inc. $194.2608/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833113 CMS
Genmab U.S., Inc. $120.0608/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833115 CMS
Genmab U.S., Inc. $240.0008/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833121 CMS
Genmab U.S., Inc. $119.6008/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833125 CMS
Merck Sharp & Dohme LLC $2,135.0007/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141633369 CMS
Genmab U.S., Inc. $318.9607/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126833127 CMS
EMD Serono, Inc. $71.7801/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246121 CMS
EMD Serono, Inc. $45.6101/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246133 CMS
EMD Serono, Inc. $25.0901/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246147 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $262.13 3
PY2020 $590.34 6
PY2021 $1,500.00 1
PY2023 $7,777.55 11
PY2024 $14,141.99 15
PY2025 $19,550.73 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,091,344.57 191
PY2024 Recipient $1,142.00 1
PY2024 Principal investigator $1,113,643.03 103
PY2023 Principal investigator $647,553.50 123
PY2022 Principal investigator $951,903.86 101
PY2021 Principal investigator $1,602,672.00 113
PY2020 Recipient $2,270.00 3
PY2020 Principal investigator $2,351,551.68 45
PY2019 Principal investigator $1,957,016.08 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $1,030.00 12/31/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724177235
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,653.38 12/31/2020 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 736743443
Principal investigator 1 AstraZeneca UK Limited $183.63 12/31/2020 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of a once daily monotherapy regimen of AZD1775 in patients with advanced solid tumours No dispute reported 06/30/2026 736735209
Principal investigator 1 AstraZeneca UK Limited $283.75 12/31/2020 Non-covered Recipient Entity
University Of Cincinnati College Of Medicine
This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of a once daily monotherapy regimen of AZD1775 in patients with advanced solid tumours No dispute reported 06/30/2026 736747625
Principal investigator 1 GlaxoSmithKline, LLC. $11,762.10 12/15/2020 Non-covered Recipient Entity
UNI CINCINNATI PHYSICIANS CO
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734913739
Principal investigator 1 GlaxoSmithKline, LLC. $103,363.20 12/15/2020 Non-covered Recipient Entity
UC HEALTH PHARMACY
AN OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY OF NIRAPARIB AND No dispute reported 06/30/2026 734916255
Principal investigator 1 GlaxoSmithKline, LLC. $99,198.00 12/15/2020 Non-covered Recipient Entity
UNI CINCINNATI PHYSICIANS CO
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734920455
Principal investigator 1 Merck Sharp & Dohme Corporation $49,349.60 12/05/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797441
Principal investigator 1 Merck Sharp & Dohme Corporation $49,349.60 12/05/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797443
Recipient PFIZER INC. $780.00 12/04/2020 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742856273
Principal investigator 1 Alkermes, Inc. $21,319.02 12/02/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724178569
Principal investigator 1 Alkermes, Inc. $10,883.96 11/24/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724177229
Principal investigator 1 Alkermes, Inc. $28,589.00 11/24/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724177231
Principal investigator 1 GlaxoSmithKline, LLC. $69,684.48 11/12/2020 Non-covered Recipient Entity
UC HEALTH LABORATORY
214358 No dispute reported 06/30/2026 965524869
Principal investigator 1 GlaxoSmithKline, LLC. $1,987.64 11/11/2020 Non-covered Recipient Entity
UC HEALTH LABORATORY
214358 No dispute reported 06/30/2026 965524867
Principal investigator 1 Merck Sharp & Dohme Corporation $3,400.00 10/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies No dispute reported 06/30/2026 740823915
Principal investigator 1 Merck Sharp & Dohme Corporation $121,551.00 10/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797439
Principal investigator 1 Merck Sharp & Dohme Corporation $145,861.20 09/25/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797363
Recipient PFIZER INC. $1,400.00 09/18/2020 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742856275
Principal investigator 1 Merck Sharp & Dohme Corporation $145,861.20 07/10/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797361
Principal investigator 1 Alkermes, Inc. $54.78 07/01/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724178285
Principal investigator 1 Alkermes, Inc. $25.55 07/01/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724178287
Principal investigator 1 Alkermes, Inc. $13.09 07/01/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724178289
Principal investigator 1 Alkermes, Inc. $7.55 07/01/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 724178293
Principal investigator 1 Merck Sharp & Dohme Corporation $249,994.00 06/26/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740844005
Principal investigator 1 GlaxoSmithKline, LLC. $89,973.00 05/21/2020 Non-covered Recipient Entity
UNI CINCINNATI PHYSICIANS CO
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734920761
Principal investigator 1 GlaxoSmithKline, LLC. $8,550.00 05/21/2020 Non-covered Recipient Entity
UNI CINCINNATI PHYSICIANS CO
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734923691
Principal investigator 1 AstraZeneca Pharmaceuticals LP $94,184.00 04/28/2020 Non-covered Recipient Entity
Uc Healthcare System
An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 736735323
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,770.00 04/21/2020 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 736737145
Principal investigator 1 Merck Sharp & Dohme Corporation $145,861.20 04/14/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797353
Principal investigator 1 Merck Sharp & Dohme Corporation $48,620.40 04/14/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797357
Principal investigator 1 Merck Sharp & Dohme Corporation $121,551.00 04/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797273
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,695.00 04/02/2020 Non-covered Recipient Entity
University Of Cincinnati
Phase I II FIH Monotherapy Nivo Combination No dispute reported 06/30/2026 736763609
Principal investigator 1 AstraZeneca UK Limited $5,005.00 04/01/2020 Non-covered Recipient Entity
University Of Cincinnati College Of Medicine
This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of a once daily monotherapy regimen of AZD1775 in patients with advanced solid tumours No dispute reported 06/30/2026 736744875
Principal investigator 1 Merck Sharp & Dohme Corporation $243,102.00 04/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797355
Principal investigator 1 Merck Sharp & Dohme Corporation $121,551.00 03/31/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740797359
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,574.39 03/26/2020 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 736743215
Principal investigator 1 AstraZeneca UK Limited $3,239.00 03/18/2020 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of a once daily monotherapy regimen of AZD1775 in patients with advanced solid tumours No dispute reported 06/30/2026 736740053
Principal investigator 1 AstraZeneca UK Limited $944.00 03/18/2020 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
The purpose of this study is to determine whether AZD1775 has any effect on the pharmacokinetics PK of three compounds No dispute reported 06/30/2026 736743861
Principal investigator 1 Merck Sharp & Dohme Corporation $132,942.88 03/12/2020 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740704131
Principal investigator 1 Merck Sharp & Dohme Corporation $1,650.00 03/11/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies No dispute reported 06/30/2026 740816539
Recipient E.R. Squibb & Sons, L.L.C. $90.00 02/27/2020 Covered Recipient Physician A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors No dispute reported 06/30/2026 736765585
Principal investigator 1 Merck Sharp & Dohme Corporation $132,942.88 02/27/2020 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 740706521
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $98.92 02/25/2020 Non-covered Recipient Entity
University Of Cincinnati Medical Center
Phase I II FIH Monotherapy Nivo Combination No dispute reported 06/30/2026 736763613
Principal investigator 1 Eli Lilly and Company $801.00 02/25/2020 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 728725863
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,074.40 02/18/2020 Non-covered Recipient Entity
University Of Cincinnati
Phase II 1L Metastatic H&N Single Arm Nivo Ipi Combo No dispute reported 06/30/2026 736763607
Principal investigator 1 Eli Lilly and Company $209.64 01/28/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 728751793
Principal investigator 1 AstraZeneca UK Limited $21,806.24 01/09/2020 Non-covered Recipient Entity
Uc Healthcare System
A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 736743471